Previous work from our group has shown that chronic homotypic stress (repeated restraint -RR) increases microglial morphological activation in the prefrontal cortex (PFC), while chronic heterotypic stress (chronic variable stress -CVS) produces no such effect. Therefore, we hypothesized that stressor modality would also determine the susceptibility of the PFC to a subsequent inflammatory stimulus (low dose lipopolysaccharide (LPS)). We found that RR, but not CVS, increased Iba-1 soma size in the PFC after LPS injection, consistent with microglial activation. In contrast, CVS decreased gene expression of proinflammatory cytokines and Iba-1 in the PFC under baseline conditions, which were not further affected by LPS. Thus, RR appears to promote microglial responses to LPS, whereas CVS is largely immunosuppressive. The results suggest that neuroimmune changes caused by CVS may to some extent protect the PFC from subsequent inflammatory stimuli. These data suggest that modality and/or intensity of stressful experiences will be a major determinant of central inflammation and its effect on prefrontal cortex-mediated functions.
Introduction
Stress-induced changes in the CNS immune environment are thought to play a major role in the development of stress related disorders, such as depression (Kreisel et al., 2014; Leonard, 2005; Hayley et al., 2003; Grippo et al., 2005; Wager-Smith and Markou, 2011) . Stress influences CNS immune responses via a variety of mechanisms, including glucocorticoid (Frank et al., 2012) or b-adrenergic receptor signaling (Porterfield et al., 2012) . Microglia, the major immune cells of the brain, show dynamic responses to stress that contribute to behavioral and hormonal consequences (Walker et al., 2013) . Stress can have differential effects on microglial function, inducing pro-or anti-inflammatory responses. In many stress-responsive brain regions, acute stress increases microglial numbers and markers of microglial activation (Kreisel et al., 2014; Johnson et al., 2002; Sugama et al., 2007; Jankord et al., 2010) . However, under persistent chronic unpredictable stress, microglial activation can become greatly reduced and the cells can even undergo apoptosis (Kreisel et al., 2014) . Reversing either the acute or chronic effects of stress on microglia can attenuate the development of stress-induced depression-like behavior (Kreisel et al., 2014) . Furthermore, antidepressant treatment can reverse both acute stress-induced microglial proliferation (Kreisel et al., 2014) and chronic stress-induced immunosuppression (Basso et al., 1993) and microglial decline (Kreisel et al., 2014) .
Conversely, there are a variety of other chronic stressors (repeated restraint stress, repeated social defeat, and chronic intermittent cold stress) that are known to enhance microglial activation in a variety of stress-responsive brain regions (Tynan et al., 2010; Gadek-Michalska et al., 2012; Wohleb et al., 2012; Reader et al., 2015; Porterfield et al., 2012; Girotti et al., 2011) . This enhanced microglial activation may potentiate central immune responses to subsequent inflammatory challenge, called priming. Stress primes CNS immune responses by enhancing microglial activation and prolonging cytokine release to a subsequent stressor or immune challenge, such as exposure to lipopolysaccharide (LPS). These enhanced microglial responses primed by stress contribute to the behavioral and hormonal consequences of stress (Hinwood et al., 2012; Gadek-Michalska et al., 2012; Wohleb et al., 2012; Grippo et al., 2005) .
Previous work by our group has shown that chronic stress modality can affect microglial activation in the prefrontal cortex (PFC) (Kopp et al., 2013) . The PFC is a major stress regulatory brain region, and PFC dysfunction is implicated in numerous stress related disorders, including major depression (Drevets et al., 1997 (Drevets et al., , 2008 Mayberg et al., 2005; Lemogne et al., 2012) . Importantly, our work suggests that the characteristics of different stress http://dx.doi.org/10.1016/j.bbi.2016.05.004 0889-1591/Ó 2016 Elsevier Inc. All rights reserved.
